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Abstract
Background: Loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) underlines much of the
pathology of Parkinson’s disease (PD), but the existence of an endogenous neurogenic system that could be
targeted as a therapeutic strategy has been controversial. BNN-20 is a synthetic, BDNF-mimicking,
microneurotrophin that we previously showed to exhibit a pleiotropic neuroprotective effect on the dopaminergic
neurons of the SNpc in the “weaver” mouse model of PD. Here, we assessed its potential effects on neurogenesis.
Methods: We quantified total numbers of dopaminergic neurons in the SNpc of wild-type and “weaver” mice, with
or without administration of BNN-20, and we employed BrdU labelling and intracerebroventricular injections of DiI
to evaluate the existence of dopaminergic neurogenesis in the SNpc and to assess the origin of newborn
dopaminergic neurons. The in vivo experiments were complemented by in vitro proliferation/differentiation assays
of adult neural stem cells (NSCs) isolated from the substantia nigra and the subependymal zone (SEZ) stem cell
niche to further characterize the effects of BNN-20.
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Results: Our analysis revealed the existence of a low-rate turnover of dopaminergic neurons in the normal SNpc
and showed, using three independent lines of experiments (stereologic cell counts, BrdU and DiI tracing), that the
administration of BNN-20 leads to increased neurogenesis in the SNpc and to partial reversal of dopaminergic cell
loss. The newly born dopaminergic neurons, that are partially originated from the SEZ, follow the typical nigral
maturation pathway, expressing the transcription factor FoxA2. Importantly, the pro-cytogenic effects of BNN-20
were very strong in the SNpc, but were absent in other brain areas such as the cortex or the stem cell niche of the
hippocampus. Moreover, although the in vitro assays showed that BNN-20 enhances the differentiation of NSCs
towards glia and neurons, its in vivo administration stimulated only neurogenesis.
Conclusions: Our results demonstrate the existence of a neurogenic system in the SNpc that can be manipulated
in order to regenerate the depleted dopaminergic cell population in the “weaver” PD mouse model.
Microneurotrophin BNN-20 emerges as an excellent candidate for future PD cell replacement therapies, due to its
area-specific, pro-neurogenic effects.
Keywords: Neurogenesis; Adult brain, Dopaminergic, Substantia nigra, Parkinson’s disease, Weaver mouse,
Microneurotrophin, BNN-20, Neurotrophic, Subependymal zone
Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, constituting a significant clin-
ical and socioeconomic problem [1]. No established
therapy to slow down, stop, or reverse the degenerative
process exists and symptomatic treatments hold signifi-
cant side effects [2, 3], although recent experimental
work has showed that the nigrostriatal pathway can be
restored by grafting [4] or reprogramming cells [5, 6].
Neurotrophic factors, such as brain-derived neuro-
trophic factor (BDNF) and glial-derived neurotrophic
factor (GDNF), are well-described candidates for the
treatment of PD, as they exhibit dual neuroprotective
and neurogenic properties. However, their clinical use is
hampered by the limited penetration of the blood-brain
barrier (BBB), due to their large molecular size and their
poor pharmacokinetic properties [2, 7–9].
Research on the pharmacotherapy of PD has recently
focused on micromolecular compounds that can mimic
the neuroprotective and neurogenic properties of
endogenous neurotrophic factors, while penetrating the
BBB. Microneurotrophins (MNTs) are micromolecular
synthetic analogues of dehydroepiandrosterone (DHEA)
that selectively bind and activate the neurotrophin re-
ceptors TrkA (of NGF), TrkB (of BDNF), and p75NTR,
mimicking the beneficial effects of growth factors, which
can also penetrate the BBB. Furthermore, MNTs are not
activating classical estrogen or androgen receptors and,
hence, are considered to be deprived of hormone-
dependent side effects [10–13].
The “weaver” mouse model is the only genetic model
of progressive nigrostriatal dopaminergic neurodegener-
ation, caused by an autosomal recessive point mutation
of the Girk2 potassium channel, with dopaminergic cell
loss in the substantia nigra pars compacta (SNpc) start-
ing on postnatal day (P) 7 and reaching the 75% of cells
on P60. The mutation leads to the loss of Girk2’s ion
specificity, and to the progressive loss of the dopamin-
ergic neurons of the SNpc and other brain regions, due
to excitotoxicity. Even though Girk2 mutations have not
been identified in human cases of PD so far, the model
exhibits many significant hallmarks of the disease, such
as neuroinflammation [13–15], oxidative stress [13, 16,
17], dopamine reduction in the striatum [15, 18], motor
deficits [15, 18, 19], a-synuclein pathology [17], reduced
levels of BDNF [13, 15], and cognitive impairment in the
more progressed stages of degeneration [19]. Hence, it
consists a phenocopy of human PD ideal for neuropro-
tection studies.
We have recently reported the strong neuroprotective
properties (antioxidant, antiapoptotic, anti-inflammatory)
of the MNT BNN-20 (17β-spiro-(androst-5-en-17,2'-oxi-
ran)-3β-ol) in the “weaver” mouse model [13, 15]. Further-
more, we have shown that BNN-20 exerts its beneficial
effects, at least in part, by activating the TrkB receptors
and their downstream signaling pathways TrkB-Akt-NFκΒ
and TrkB-ERK1/2-NFκΒ, triggering an NFκΒ-dependent
positive feedback loop, which leads to the increase of
BDNF itself [13, 15].
During the last two decades, the existence of neuro-
genesis in noncanonical sites of the adult rodent brain
has been increasingly supported by several research
groups [20, 21]. However, the occurrence of adult
dopaminergic neurogenesis in the SNpc remains contro-
versial until now [22–28]. Here, we use exhaustive dopa-
minergic neuron cell counts and we employ BrdU and
DiI cell tracing analyses, in order to investigate the exist-
ence of endogenous dopaminergic neurogenesis in the
SNpc of postnatal wild-type and “weaver” mice, as well
as the possible beneficial effect of BNN-20 on it. Our
findings demonstrate that new dopaminergic neurons
are generated in the normal and the degenerated SNpc
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and that this system can be exogenously manipulated.
Administration of BNN-20 led to the specific increase in
dopaminergic SNpc neurogenesis, without affecting
gliogenesis and the hippocampal neural stem cell niche.
These, along with our recently published results, make
BNN-20 a strong candidate molecule for the treatment
of PD.
Methods
Animal maintenance and handling
All experiments were performed with male and female
homozygous “weaver” (Aw-J/A-Kcnj6wv/J) mice of the
B6CBAC strain and age-matched B6CBAC wild-type an-
imals. The breeding and handling of the animals was
performed in accordance to the European Communities
Council Directive Guidelines (86/609/EEC) for the care
and use of Laboratory animals as implemented in Greece
by the Presidential Decree 56/2013 and approved and
scrutinized by the Prefectural Animal Care and Use
Committee (No: EL 13BIO04) and the Animal Welfare
and Ethical Review Committee of the University of Pa-
tras. Animals were maintained in steady light/dark cycle
(12/12 h) with free access to food and water. Identifica-
tion of homozygotes (here called “weaver” or wv) was
performed based on behavior and randomly confirmed
by PCR. “Weaver” phenotype involved weakness, hypo-
tonia, extensive periods of resting and movement-
initiated tremor, poor limb coordination, and instability
of gait (due to their underdeveloped cerebellum) [29].
“Weaver” mice were fed daily with a paste consisting of
standard rodent food pellets and water, as they are un-
able to reach the water bottles, due to their limited mo-
bility. They are smaller in size and have increased
morbidity, especially before weaning.
BNN-20 (1mg/ml in 1% ethanol, 0,9% NaCl) (Bionature
E.A. Ltd, Nicosia, Cyprus) or vehicle was administered via
i.p. injection daily (100mg BNN-20 per kg b.w.), during
P14–P40 or P14–P60. For the labelling of proliferating
cells, bromodeoxyuridine (BrdU) was dissolved in
phosphate-buffered saline (PBS) (1mg/ml) and adminis-
tered daily via i.p. injections (100mg/kg b.w.), from P20 to
P40 or from P40-P60 (Additional Figure 1).
For immunofluorescence analyses, mice were killed on
P40 or P60 by intracardial perfusion of 4% paraformalde-
hyde. Brain tissue was cryoprotected and sliced using a
Bright Cryostat (Leica, CM1500) in sections of 15 μm. For
neural stem cell (NSC) cultures, mice were killed by cer-
vical dislocation and the SEZ, or the area containing the
substantia nigra (referred from now on as SN), were dis-
sected under the stereoscope using anatomical landmarks.
NSC cultures
The SEZ, or the broader midbrain area of the substantia
nigra (carefully excluding all of the periventricular areas)
(SN), were dissected under a stereoscope, were dissoci-
ated in accutase (37oC, 15 min; BIOWEST), and were
resuspended in NSC proliferation medium [Dulbecco’s
modified Eagle’s medium − high glucose + pyruvate
(Thermo Fisher Scientific 11965-084), 20 ng/ml FGF-2
(Peprotech), 20 ng/ml EGF (Peprotech), and 2% B27
(Gibco, 17-504-044)]. NSCs grew as 3D free-floating
aggregates called neurospheres that could be passaged.
In proliferation or differentiation assays, dissociated neu-
rosphere cells were plated on glass coverslips, coated
with poly-D-lysine (PDL), in the presence of either the
standard NSC medium (proliferation assays), or after
withdrawal of growth factors [in DMEM, 2% B27, 1% N2
(Thermo Fisher)], respectively. Cells were kept for 5 days
for proliferation (5dp) and 3, 5, or 7 days (3dd, 5dd, 7dd)
for differentiation. BNN-20 (100 nM) was added in the
medium for the total culture duration. Cells were fixed
with 2% PFA and immunostained. In cell proliferation/dif-
ferentiation assays, cell counts were performed in at least
5 random optical fields per coverslip per experiment.
In the primary neurosphere assays, spheres were spun
down and plated on PDL-coated coverslips, allowed to
adhere and subsequently fixed and immunostained. Neu-
rosphere size was calculated by measuring their diameter
using ImageJ. In the spontaneous neurogenesis assess-
ment experiment, primary spheres were grown in prolif-
eration medium and were counted as βIII tubulin+ if
they included even one βIII tubulin+ cell.
Dopaminergic neuron quantifications in the SNpc
The total number of dopaminergic neurons of the sub-
stantia nigra pars compacta (SNpc) was evaluated by
DAB immunostaining for the tyrosine hydroxylase (TH)
dopaminergic cell marker. Images were obtained with
the × 10 objective (Zeiss, Axio Lab.A1). The SNpc was
determined based on the stereotaxic coordinates of
Frankin & Paxinos [30]. The total TH+ cell number of
the SNpc was quantified stereologically: all TH+ cells
were counted in both hemispheres in 10 equally distanced
sections (100 μm step) in each animal (n = 4 per group).
The total dopaminergic cell number was determined using
the following formula, appropriate for stereological cell
quantification [31] as performed previously [13, 15]:
Number of neurons = 1/ssf (slice sample fraction) × 1/
asf (area sample fraction) × 1/tsf (thickness sampling
fraction) × number of objects counted
DiI labelling
Neural stem and progenitor cells (NSPCs) of the SEZ
were labelled via stereotaxic injection of the lipophilic
dye DiI, as has been previously described [25]. Briefly,
2 μl of DiI solution [10% DiI in dimethyl sulfoxide
(DMSO), Sigma] was injected unilaterally in the lateral
ventricle of P45 mice (n = 3 per animal group), at the
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following coordinates from bregma [30]: anterior 5 mm;
left 0.65 mm; depth 2.3 mm. BNN-20 or saline was co-
administered during P14–P60, as described in “Animal
maintenance and handling”. Mice were killed after 15
days (at P60).
Immunofluorescence on brain sections
Tissue sections were thawed and post-fixed with 4%
paraformaldehyde for 5 min. For nuclear antigens, a step
of antigen retrieval was applied (citrate buffer 0.1M, pH
= 6.0; 100oC for 15 min). For BrdU detection, an add-
itional step of DNA denaturation was used, by incubat-
ing the sections in 2M HCl for 1 h at 37 °C, followed by
pH neutralization using sodium borate buffer (0,1 M, pH
8.5). Sections were blocked in 10% normal donkey
serum. Primary antibody incubation was performed
overnight at 4 °C. Secondary antibody incubation was
performed for 1 h at RT, using appropriate antibodies
conjugated with fluorescent dyes (appropriate Alexa-
Fluor Donkey IgG, 568, 488, or 647, Thermo Fisher
Scientific). The list of the used primary antibodies and
appropriate dilutions used for immunofluorescence for
both brain sections and cell cultures is given below:
Ascl1 (MASH-1) [mouse monoclonal, Clone 24B72D11.1
(RUO), BD Bioscience, 556604 (1:100)]; BrdU [rat
monoclonal [BU1/75 (ICR1)], Abcam, ab6326 (1:150)];
doublecortin (Dcx) [rabbit polyclonal, Abcam, ab18723
(1:500)]; GFAP [chicken, Abcam, ab4674 (1:500)]; GFAP
[goat polyclonal, Abcam, ab53554 (1:500)]; GFAP
[mouse monoclonal, Merck-Millipore, G6171 (1:500)];
HNF-3β (FoxA2) [mouse monoclonal (RY-7), SantaCruz
Biotechnologies, sc-101060 (1:200)]; Ki67 [rabbit poly-
clonal [SP6], Abcam, ab16667 (1:500)]; PCNA [mouse
monoclonal [PC10] (ab29) (1:500)]; phosphohistone 3
(PH3) [rabbit polyclonal (phospho S10), Abcam, ab5176
(1:500)]; Sox2 [goat polyclonal (Y-17), SantaCruz Bio-
technologies, sc-17320 (1:200)]; tyrosine hydroxylase
(TH) [rabbit polyclonal, Merck-Millipore, AB152 (1:
300)]; β-ΙΙΙ-tubulin [mouse monoclonal [TU-20], Abcam,
ab7751 (1:500)]. Images were obtained by fluorescence
(Zeiss, Axio Observer.D1) or confocal (Leica TCS SP8)
microscopy, using the × 40 and × 63 objectives for brain
sections and cells, respectively, and were saved in a
high-resolution .tiff format. Quantifications were per-
formed using the LasX (Leica), ImageJ, and Adobe
Photoshop CS6 software. For the cell-type profile ana-
lysis in the SNpc, the SEZ and the cortex images of at
least 5 random optical fields were taken from each area
of both hemispheres, from at least 3 brain sections per
animal. In the absence of TH immunostaining, the SNpc
was identified using anatomical landmarks and adjacent
sections already stained for TH. After BrdU immunostain-
ings, the nuclear counterstaining was of low quality; there-
fore, total nuclei were not quantified. For quantifications
in the SEZ, optical fields were obtained from at least three
distant areas along the dorso-ventral axis (dorsal, middle,
and ventral SEZ) and cells were counted within a 30-μm
zone from the ventricular surface that includes the niche
[32]. Quantifications of BrdU+ cells within the hippocam-
pus were performed by counting total immunopositive
cells in at least 3 optical fields per hippocampus in at least
3 sections per animal and the numbers were normalized
per length of the SGZ zone.
PCR for genotyping for the “weaver” (Girk2) mutation
DNA primers sequences used for genotyping are pro-
vided below (5′➔3′):
“wild-type”-specific forward primer: GAGACAGAAA
CCACCATCG
“weaver”-specific forward primer: GAGACAGAAA
CCACCATCA
Reverse primer (common for both genotypes):
CACGGACTGGATTAAGAGGAGAATAAT
The PCR protocol used was the following (27 cycles):
(i) pro-incubation (95 °C, 15 min), (ii) denaturation
(95 °C, 30 s), (iii) annealing (54.5οC, 30 s), (iv) extension
(72 °C, 1 min), (v) final step (72 °C, 10 min).
Cell counts—analysis of morphology
For morphological analysis of dopaminergic cells, images
from sections immunostained for TH and FoxA2 were
taken using confocal microscopy with the × 63 objective lens
and a further zoom = 2, at 0.10 μm steps (n = 10 cells per
group from 2 animals). The longest dimension of the cell
body was identified and measured (all measurements taken
using the LasX software), followed by measurement of the
maximum length at the perpendicular axis and the calcula-
tion of the depth of the cell body using the number of steps
that included each cell (Visual details on the morphological
analysis methodology are provided as Additional Mater-
ial (See Additional File 2)). One-way ANOVA was employed
for each dimension, followed by post hoc analysis.
Statistics
Statistical analysis was performed by Student’s t test,
one-way ANOVA, or two-way ANOVA (depending on
the experimental design) using IBM SPSS Statistics 25
and Microsoft Excel. In cases of statistically significant
differences (p < 0.05), ANOVAs were followed by either
LSD or Bonferroni post hoc analysis for multiple com-
parisons between groups.
Results
Long-term BNN-20 treatment inhibits and partially
reverses further TH+ cell loss in the SNpc of the “weaver”
mouse
We have previously shown the strong neuroprotective
effect of early BNN-20 administration (postnatal days
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P0-P20, before the initiation and during the first stages
of neurodegeneration) on the dopaminergic neurons of
the “weaver” (wv) SNpc, including its protective effect
on their terminals in the striatum, as well as at a later
stage of degeneration (P14–P60), when administration
begins after 41% of the dopaminergic neurons are
already depleted [13, 15]. Our next goal was to evaluate
the significance of the length of BNN-20 administration
with a starting point at P14. To do so, we administered
BNN-20 in two schemes: from P14 to P40 and from P14
to P60. As expected, we documented further progressive
loss of TH+ neurons in the “wv” SNpc: 41% at P14 that
increased to 50% by P40 and reached 68% by P60
(Fig. 1A, B). Daily administration of BNN-20 during
P14–P40 not only completely abolished further
degeneration, but also significantly increased TH+ cell
numbers in the SNpc by 26%, in respect to the P14
starting point, indicating the possible induction of a
neurogenic process. Nevertheless, the numbers of
TH+ neurons in the “weaver” SNpc remained signifi-
cantly depleted (by approximately 29%), compared to
age-matched wild-type (WT) mice (Fig. 1A, B).
Longer BNN-20 administration (P14–P60) was equally
efficient at blocking further degeneration and led to a
slight increase in the number of TH+ neurons (in the
wv BNN-20 P14–P60 SNpc compared to wv P14), al-
though this increase was not statistically significant.
TH+ cell number in the wv BNN-20 P14–P60 SNpc
remained significantly reduced by 32% compared to
age-matched wild-type mice (Fig. 1A, B). Administra-
tion of BNN-20 in WT mice had no impact on TH+
cell numbers of the SNpc (Additional File 3).
Low-level dopaminergic neurogenesis exists in the SNpc
of wild-type and “weaver” mice and is significantly
enhanced by BNN-20
In order to investigate if the appearance of increased
numbers of dopaminergic neurons in the adult weaver
SNpc after the administration of BNN-20 was the result
of neurogenesis, we decided to use BrdU labelling.
Initially, we administered BrdU for 7 days, but we failed
to identify double-positive BrdU/TH cells (data not
shown). This indicated that a longer pulse was necessary,
as expected for the differentiation/ maturation of newly
born neurons and confirmed the absence of acute BrdU
incorporation in dopaminergic neurons that could imply
cell repair [33]. Based on previously published long-term
BrdU administration schemes [34], we chose to apply
two distinct BrdU schemes, both involving daily admin-
istration of BrdU for 20 consecutive days (see Additional
File 1). Initially, we administered BNN-20 or saline (sal)
from P14 to P60 in WT and wv mice with co-
administration of BrdU between P40 and P60. Our data
regarding the total number of TH+ cells in all four
experimental groups revealed no indication of BrdU-
induced toxicity (compare Figs. 1 and 2A, B). The pres-
ence of newborn dopaminergic neurons (TH+/BrdU+)
at P60 was evaluated by immunofluorescence (Fig. 2C)
and confocal (Fig. 2D) microscopy. BrdU+/TH+ double-
positive dopaminergic neurons were detected in the
SNpc of all experimental groups, indicating the presence
of adult dopaminergic neurogenesis in the SNpc (Fig.
2A, B). Interestingly, the administration of BNN-20 led
to a significant rise in the appearance of newborn TH+
cells in the WT SNpc, increasing their average number
Fig. 1 Effects of BNN-20 administration on the total dopaminergic cell number of the “weaver” SNpc. A Dot plot of stereologically calculated
total TH+ cell numbers in the SNpc of wild-type (WT) and “weaver” (wv) mice, treated with either BNN-20 or saline (sal) from P14 to P40 or to
P60 (n = 4 per group) [a: p < 0.001 compared to WT P14, b: p < 0.01 compared to wv P14, c: p < 0.001 compared to wv P40, d: p < 0.001
compared to wv P60, using two-way ANOVA followed by Bonferroni post hoc test (p = 0.000, F = 52.160 for drug, p = 0.000, F = 100.234 for
genotype and p = 0.000, F = 12.114 for the interference of the two variables). Error bars are SDs.]. B Representative images of the SNpc using
DAB immunohistochemistry against TH [scale bar= 200 μm]
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from 346 ± 77.49 to 1389.7 ± 208.16 per SNpc, and their
average contribution to the total TH+ cell population
from 4.03 ± 0.09% to 17.28 ± 2.28% (Fig. 2A,B). How-
ever, despite this increase, BNN-20 did not affect the
total TH+ cell number in the WT SNpc (Fig. 2A,B; total
TH+ cell numbers in the WT SNpc post BNN-20
administration are provided as Additional Material—
(See Additional File 3)).
In the wv sal SNpc, the absolute number of double-
positive cells was similar to the one observed in the WT
sal SNpc (414.72 ± 32.07 per SNpc on average), but their
contribution to the depleted pool of dopaminergic
neurons was dramatically increased, making on aver-
age the 17.43 ± 1.28% of all TH+ cells (Fig. 2A).
More importantly, BNN-20 administration signifi-
cantly enhanced the presence of new dopaminergic
neurons in the wv SNpc, increasing their average
number to 1357.44 ± 100.68 and their contribution to
26.69 ± 2.02% of all TH+ cells (Fig. 2A).
In order to investigate whether newborn neurons
survive longer, we applied a second BrdU protocol, with
BNN-20/sal administered from P14 to P60 (as previ-
ously) and co-administration of BrdU again for 20 days,
but this time between P20 and P40 (see Additional File
1). Mice were sacrificed at the same time-point (P60),
allowing a 20-day BrdU withdrawal period. In agreement
with our previous findings, newborn dopaminergic neu-
rons were detected in the SNpc of all experimental
groups with their absolute numbers and fraction per
total TH+ cells being at similar levels to the 1st protocol
(Fig. 2B).
The newborn dopaminergic neurons follow the canonical
SNpc differentiation pathway, expressing FoxA2
Dopaminergic neurons in the SNpc express TH, as well
as specific transcription factors such as Nurr1, FoxA2,
and Pitx3 that are necessary during specification, matur-
ation, and survival. Notably, FoxA2 is considered to be a
Fig. 2 Newborn TH+/BrdU+ neurons in the postnatal WT and wv mouse SNpc; effects of BNN-20. A,B Stereologically calculated numbers of total TH+
cells in the SNpc of wild-type (WT) and “weaver” (wv) mice that received BNN-20 or saline (sal) from P14 to P60, with co-administration of BrdU from
P40 to P60 (in A), or from P20 to P40 (in B). Co-expression of BrdU is also shown (TH+/BrdU+ cells, in light blue/pink and TH+/BrdU− in dark blue/red)
[Graph A: n = 3 per group, TH+/BrdU+ to total TH+ percentage comparison: a: p < 0.01 compared to WT sal. b: p < 0.05 compared to wv sal. c: p <
0.05 compared to WT BNN-20. Graph B: n = 3 per group, a: p < 0.001 compared to WT sal. b: p < 0.001 compared to wv sal. c: p < 0.001 compared to
WT BNN-20. Statistical analysis was performed by two-way ANOVA followed by Bonferroni post hoc test (p < 0.001, F = 41.993 for drug, p < 0.001,
F = 42.679 for genotype). Error bars are SEMs]. C,D Representative images after immunofluorescence stainings against TH and BrdU in the SNpc of
C a cluster of TH+/BrdU+ cells observed in the SNpc of wv BNN-20 mice (fluorescence microscopy) and D in the SNpc of WT BNN-20 mice (confocal
microscopy). Double-positive (TH+/BrdU+) newborn dopaminergic neurons are indicated by white arrows [scale bar= 50 μm]
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crucial transcription factor for the acquisition, function,
and preservation of the mesencephalic dopaminergic
phenotype [35, 36]. We assessed cell-type profiles in the
SNpc of all experimental groups using high-magnification
immunofluorescence analysis for TH and FoxA2 (Fig. 3A,
B). In WT mice, we identified the typical dopaminergic
neurons (TH+/FoxA2+) complemented by a pool of
FoxA2+ only immunopositive cells and a small, previously
undescribed population of TH+/FoxA2- neurons account-
ing for 5.12 ± 3.36% and 12.62 ± 3.54% of the total TH+
cells in the SNpc of WT sal and wv sal SNpc, respectively
(Fig. 3A,B). In wv mice, both the density of total TH+ and
of TH+/ FoxA2+ cells were significantly reduced (Fig. 3A),
while the density and the percentage of FoxA2 + only cells
Fig. 3 FoxA2 expression in the dopaminergic cell lineage of the SNpc. A Cell densities of the different subpopulations within the dopaminergic
lineage (based on expression of TH and FoxA2) A in the SNpc of wild-type (WT) and “weaver” (wv) mice that received BNN-20 or saline (sal) from
P14 to P60 and Β a characteristic example of immunostaining (with some of the TH+/ FoxA2− cells indicated by white arrows, and some of the
TH+/FoxA2+ cells indicated by yellow arrows) [scale bar= 50 μm. a: decreased total TH+ cell densities (p < 0.05) compared to WT BNN-20 and WT
sal groups (F = 7.94, p = 0.023 for genotype); b: increased TH+/FoxA2− densities (p < 0.05) compared to WT and wv sal groups (F = 25.971, p =
0.001 for drug), using two-way ANOVA followed by LSD post hoc analysis. n = 3 animals per group. Error bars are SEMs.]. C TH+/BrdU+ cell
densities per optical field in the SNpc of the WT sal and WT BNN-20 groups, also showing the co-expression of FoxA2 [a: increased TH+/BrdU+/
FoxA2+ and TH+/BrdU+/FoxA2− densities compared to WT sal; p < 0.05, using Student’s t test, n = 3 animals per group. Error bars are SEMs]. D
Percentage of the newly described TH+/FoxA2− cells within the pools of total TH+ cells (in dark red), older (TH+/BrdU−, in blue), and newborn
(TH+/BrdU+, in yellow) dopaminergic neurons in the WT SNpc post-administration of BNN-20 or saline (sal) (P14–P60) [a: increased % TH+/FoxA2
− percentage compared to WT sal; p < 0.05, using Student’s t test, n = 3 animals per group. Error bars are SDs]. E A characteristic example of
immunostaining indicating the 3 dopaminergic subpopulations of the SNpc: TH+/BrdU+/FoxA2+ (white arrow), TH+/BrdU−/FoxA2+ (cyan arrow),
and TH+/BrdU−/FoxA2− (yellow arrow) [scale bar= 50 μm]
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(Fig. 3A and data not shown) remained at normal levels.
Interestingly, the administration of BNN-20 significantly in-
creased the density of TH+/FoxA2− cells in the SNpc of
both the WT (4.2-fold) and wv (2.3-fold) mice, to 21.48 ±
3.29% and 29.08 ± 1.35%, respectively (Fig. 3A,B).
Notably, almost all newborn dopaminergic neurons
(TH+/BrdU+) were also FoxA2+, with an average of
98.04 ± 1.96% and 93.82 ± 2.18% of TH+/BrdU+
neurons in the WT sal and WT BNN SNpc, respectively,
being FoxA2+ (Fig. 3C–E).
This result implies that newborn dopaminergic
neurons (irrespective of whether they have been induced
by BNN-20) follow the canonical pathway for the SNpc
differentiation and express FoxA2.
In contrast, the percentage of FoxA2− cells in both the
total TH+ and the older TH+/BrdU− cell subpopula-
tions is higher, with BNN-20 administration significantly
increasing their percentage in the older (TH+/BrdU−)
cells (from 9.43 ± 1.56% to 44.48 ± 10.28% on average)
(Fig. 3D).
As the population of TH+/FoxA2− cells has not been
reported before, we compared their morphology with
that of the typical dopaminergic neurons of the SNpc
(TH+/FoxA2+) and of the TH+/FoxA2− cells of the
olfactory bulbs, a cell population constantly renewed by
adult neural stem cells (Additional File 4). All three
groups of cells were of a broadly similar elongated, pyr-
amidal morphology, with one long dimension parallel to
the coronal level and two shorter perpendicular dimen-
sions, the shortest along the sagittal level. The ratio of
the three dimensions was on average 3.9:1.7:1 for typical
dopaminergic neurons in the SNpc, 3.2:1.9:1 for the
TH+/FoxA2− cells of the Nigra and 3.0:2.1:1 for the
TH+ interneurons of the OBs. One-way ANOVA for
each dimension revealed that each cell group differed
significantly from the other two at the longest and the
shortest dimensions, with OB cells being always the
smallest and TH+/FoxA2− significantly smaller than
TH+/FoxA2+ cells (Additional File 4A-F).
BNN-20 has no effect in stem and progenitor cells of the
major neurogenic niches of the adult mouse brain
Our findings suggested the existence of neurogenic ac-
tivity within the SNpc, which is not a typical neural stem
and progenitor cell (NSPC) niche of the postnatal mouse
brain. We, therefore, complemented these observations,
by assessing the possible effects of BNN-20 on endogen-
ous pools of NSPCs, residing in the major cytogenic
niches located in the subependymal and subgranular
zones [37]. We counted the number of BrdU+ cells in
the subgranular zone (SGZ) of the dentate gyrus, in the
hippocampus of WT and wv animals that received
BNN-20/sal from P14 to P60 with co-administration of
BrdU during P20-P40. BrdU+ cells were significantly
increased by approximately 50% in the wv SGZ, com-
pared to age-matched WT mice (Fig. 4A, B); however,
the administration of BNN-20 had no effect on the num-
bers of BrdU+ cells in both genotypes.
In the SEZ, neurogenesis as judged by the density of
transit amplifying progenitors (Ascl1+ cells) and of neu-
roblasts (doublecortin+ cells) remained at normal levels
in the wv mice (compared to WT), and after the admin-
istration of BNN-20 (Fig. 4C, D). Proliferation (PCNA+
cells) was significantly reduced in the wv SEZ, especially
in the pool of neuroblasts (PCNA+/Dcx + cells), with
BNN-20 administration having no effect on proliferation
of both WT and wv NSPCs (Fig. 4C).
The subependymal zone niche contributes to
dopaminergic neurogenesis of the SNpc
Based on previously published data [25, 27], we investi-
gated the origin of newborn dopaminergic neurons by
labelling and tracing SEZ-derived cells, using unilateral
intracerebroventricular injections of DiI on P45. DiI was
evenly distributed on the ventricular walls [Images of
DiI labelling throughout the ventricular system are
provided as Additional Material (See Additional File 5)],
including the domains where NSPC populations reside.
15 days post injection (P60), we were able to detect
double-positive DiI+/TH+ neurons in the SNpc of all
experimental groups (Fig. 5A–D). This finding strongly
indicates that the SEZ contributes newborn dopamin-
ergic neurons to the SNpc. The majority of DiI+/TH+
cells in the SNpc co-expressed FoxA2, suggesting that
the SEZ-derived newborn neurons are following the
typical developmental pathway of nigral dopaminergic
neurons (Fig. 5E, F). Moreover, similarly to what we ob-
served for the BrdU+/TH+ pool of newborn dopamin-
ergic cells in the SNpc (Fig. 3B, C), the fraction of TH+/
FoxA2− neurons within the pool of SEZ-derived DiI+/
TH+ cells was very low, compared to the average per-
centage of TH+/FoxA2− cells within the total pool of
TH+ cells in the SNpc, and was not affected by BNN-20
administration, with the average percentage of DiI+/
TH+ neurons that were also FoxA2+ being in the range
of 91.67–93.33% between groups (Fig. 5E, F).
BNN-20 enhances neurogenesis in SN-derived primary
NSPC cultures
Postnatal brain NSPCs can be isolated and cultured in
the form of 3D cell aggregates called neurospheres. In
order to investigate the effects of BNN-20 on NSPCs, we
used an ex vivo approach by isolating NSPCs from the
SN of WT and wv (Ρ90) mice that had received BNN-
20/sal between P14 and P60. Primary neurospheres were
generated and we performed immunofluorescence
analysis for proliferation, progenitor identity, and dif-
ferentiation markers (Fig. 6).
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Neurospheres derived from the SEZ or the SN of WT
animals were of similar size irrespective of prior BNN-
20 administration (data not shown). However, neuro-
spheres grown from the SN of wv mice that had received
BNN-20 were significantly smaller, compared to those
grown from wv mice having received saline (Fig. 6A, B).
Primary neurospheres were immunostained for β-ΙΙΙ
tubulin (to mark immature neurons), GFAP (to mark
astrocytes), and Sox2 (to mark NSPCs). As expected,
spontaneously differentiated βIII tubulin+ cells were
almost undetectable in WT SN-derived neurospheres
grown in proliferation medium (Fig. 6C, D). Interest-
ingly, the percentage of neurospheres containing at least
one such β-ΙΙΙ tubulin+ cell was significantly increased,
almost 28-fold (to 66.48 ± 5,90%), in the wv SN cultures
(Fig. 6C, D) compared to WT, while the administration
of BNN-20 led to a significant increase in the fraction of
neurospheres containing β-ΙΙΙ tubulin+ cells in both WT
and wv mice. Impressively, almost all primary SN neuro-
spheres derived from wv mice that had received BNN-20
included β-ΙΙΙ tubulin+ cells (95.46% ± 2.01%) (Fig. 6C,
D).
In order to investigate whether the pro-neurogenic ef-
fect of BNN-20, documented in vivo and ex vivo, was
direct on NSPCs or indirect (i.e., mediated by BNN-20
altering the microenvironment of the SN [13], we de-
cided to culture SEZ and SN-derived neurospheres
(from untreated animals) with or without the presence
of BNN-20 in the medium. In order to eliminate any
“memory” of the in vivo microenvironment, in these cell
Fig. 4 Lack of effect of BNN-20 administration on the main neurogenic zones of the postnatal brain. A Dot plot of numbers of BrdU+ cells per
length and B representative immunofluorescence images of BrdU+ cells in the subgranular zone (SGZ) of the dentate gyrus (DG) of the
hippocampus [n = 3 per group. Scale bar 200 μm. Error bars are SDs. a: p < 0.05 compared to the respective WT group, using two-way ANOVA
(p = 0.002, F = 18.881) followed by LSD post hoc test]. C Histogram of the cell density of transient neural progenitors (Ascl1), proliferating cells
(PCNA+), neuroblasts (Dcx+), and Dcx+/PCNA+ cells in the SEZ [n = 2 mice per group. a: p < 0.05 compared to WT sal. Analysis was performed
by two-way ANOVA (PCNA+ comparison: p = 0.009, F = 8.902 for genotype, PCNA+/Dcx + comparison: p = 0.001, F = 18.030 for genotype)
followed by LSD post hoc test. Error bars are SDs.]. D Representative immunofluorescence images of PCNA+ and Dcx+ cells within the SEZ of WT
or wv mice post-administration of BNN-20 or saline (sal) during P14–P60 [scale bars = 200 μm]
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assays we used neurospheres that had been passaged at
least 4 times (> P4 < P8). The few neurospheres grown
from WT SN could not be passaged more than once;
thus, they could not be included in this line of experi-
ments. In SEZ-derived WT neurospheres, the addition
of BNN-20 in the medium during 3, 5, or 7 days of
differentiation (dd) resulted in a significant increase
(consistently higher than 50%) in the appearance of Dcx
+ immature neurons (Additional File 6A, C), as well as
in a significant increase in GFAP+ astrocytes (Additional
File 6B, D). Moreover, the addition of BNN-20 in the
medium during 5dd also resulted in a significant in-
crease (of 61.7 ± 16.98%) in the appearance of more ma-
ture β-ΙΙΙ tubulin+ neurons (Fig. 7A). Exposure to BNN-
20 for 5 days in proliferation conditions had no effect on
WT SEZ-derived NSPCs, as judged by the percentages
of cells immunopositive for proliferation markers Ki67
(data not shown) and phosphohistone 3 (PH3) (Fig. 7D).
In contrast to WT mice, wv SN-derived neurospheres
could be efficiently passaged, and thus used for investi-
gating the in vitro effects of BNN-20 along with SEZ-
derived cultures. Similarly to what we saw in the WT
NSPC cell cultures, BNN-20 addition in the cell culture
medium for 5 days of differentiation also led to a
significant increase in the appearance of β-ΙΙΙ-tubulin+
neurons, both in wv SEZ (by 110.8 ± 14.7%) and SN-
derived (by 42.63 ± 14.69%) neurospheres (Fig. 7B).
Addition of BNN-20 for 5 days in the proliferation
medium did not change the presence of PH3+ cells in
wv SEZ-derived neurospheres, but significantly increased
the percentage of PH3+ cells in SN-derived neuro-
spheres (Fig. 7E).
These results indicate that BNN-20’s neurogenic effect
is mainly attributed to its ability to promote the differen-
tiation of NSPCs towards neurons and, to a much lesser
extent, to any effects in NSPC proliferation.
BNN-20 increases the presence of newborn NSPCs in the
wild-type SNpc without affecting astrogliogenesis
Our data suggested that BNN-20 was able to induce a
neurogenic response in normal WT mice and that this
response was taking place in the SNpc, outside the ca-
nonical neural stem cell niches. In order to investigate
further these unexpected results, we performed add-
itional immunohistochemical analyses in WT mice that
had received BNN-20 (P14–P60) in combination with
BrdU pulses (P20–P40). We performed co-stainings for
BrdU and for Ascl1 to identify transit amplifying pro-
genitors (the direct daughter cells of neural stem cells in
the SEZ) [38], or for Sox2 (a key transcription factor
Fig. 5 Contribution of the SEZ in dopaminergic neurogenesis in the SNpc. A–D Characteristic images of DiI+/TH+ newborn dopaminergic
neurons in the SNpc (indicated by white arrows), derived from the SEZ neurogenic niche of the adult brain [scale bar = 50 μm]. E Profile of DiI+
dopaminergic (TH+) neurons of the SNpc in wild-type (WT) and “weaver” (wv) mice, after BNN-20 [or saline (sal)] administration, based on co-
expression of FoxA2 [n = 2 mice per group. Error bars are SEMs. Statistical analysis was performed using two-way ANOVA followed by Bonferroni
post hoc test]. F Representative triple immunofluorescence image depicting a cluster of DiI+/TH+ neurons in a WT BNN-20 SNpc. The white
arrow indicates a TH+/DiI+/FoxA2+ cell and the yellow arrow a TH+/DiI+/FoxA2− dopaminergic neuron [scale bar = 50 μm]
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expressed in NSPCs and activated astrocytes) and GFAP.
We focused our analysis in the SNpc and the cerebral
cortex (area V2MM), a structure known to harbor latent
NSPCs [39, 40]. In saline-treated WT mice, BrdU+ cells
were detected in the SNpc and the cortex (Fig. 8A). We
could not detect any Ascl1 immunopositive cells outside
the SEZ and a population of Sox2+ cells of equal density
was present in the two areas (Fig. 8B). After administra-
tion of BNN-20, we confirmed a significant increase in
the density of BrdU+ cells in the SNpc, which was not
detected in the cortex (Fig. 8A). BNN-20 did not lead to
the appearance of Ascl1+ cells in either area, but had a
dual effect on Sox2+ cells, only in the SNpc. It led to a
significant decrease in their total density (Fig. 8B) but in-
creased the percentage of newborn Sox2+ cells (co-ex-
pressing BrdU) in the total Sox2+ cell pool by 104.66%
(Fig. 8C), hence, confirming a pro-differentiation effect
combined with a sustained progenitor pool in the af-
fected SNpc, respectively. Astrogliogenesis was very low
in the WT SNpc and cortex, as we failed to detect
double BrdU+/GFAP+ and the density of Sox2+/GFAP+
cells that would mark activated or immature astrocytes
was decreased after BNN-20 administration, this being
significant in the cortex (Fig. 8D). Overall, this analysis
Fig. 6 In vivo BNN-20 administration enhances differentiation of isolated NSCs into neurons, in primary cell cultures. A Histogram showing the
average diameter of primary neurospheres generated from the SN of weaver mice having received saline or BNN-20 (P14–P60) [a: p < 0.05
compared to wv sal. Analysis was performed using Student’s t test, n = 5 optical fields per group. Error bars are SEMs.]. B Representative images
after immunofluorescence staining for the NSPC markers Sox-2 (green) and nestin (red), as well as for the proliferation marker PCNA (white) [scale
bars = 100 μm]. C Dot plot showing the percentage of SN-derived primary neurospheres containing at least one cell expressing the neuronal
marker β-ΙΙΙ tubulin. Neurospheres were generated from SN of wild-type (WT) and “weaver” (wv) mice that had received BNN-20 or saline (sal)
(P14–P60) [Error bars are SDs. a: p < 0.05 & a’: p < 0.01 compared to WT sal. b: p < 0.01 compared to WT BNN-20. c: p < 0.01 compared to wv sal.
Analysis performed using two-way ANOVA followed by LSD post hoc test (p < 0.001, F = 24.207 for drug, p < 0.001, F = 245.576 for genotype,
n = 5 optical fields per group)]. D Representative images after immunofluorescence staining for the NSPC marker Sox-2 (green) and the
differentiation markers GFAP (white) and βIII tubulin (red) [scale bars= 100 μm]
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revealed a dual specificity in the effects of BNN-20: the
microneurotrophin led to an increase in BrdU+ cells in
the SNpc and not in the cortex, without enhancing
astrogliogenesis.
Discussion
Recruiting endogenous NSPCs of the adult brain, rather
than resorting to transplantations or in vivo cell repro-
gramming [4–6] for the treatment of neurodegenerative
diseases, such as Parkinson’s disease, in which selective
replacement of neural cells can be effective for [41, 42],
would be highly desirable. However, the existence of
endogenous dopaminergic neurogenesis in the SNpc that
could be targeted in cases of PD remained poorly inves-
tigated and controversial, with few research groups
reporting the detection of adult-born dopaminergic neu-
rons in healthy mice and rats [24, 27, 43], and few others
failing to reproduce these results [22–24, 26, 44, 45].
Similarly contradictory results have been reported for
the induction of dopaminergic neurogenesis in the SNpc
in chemotoxic parkinsonian rodent models, such as 6-
OHDA and MPTP [26, 44, 45].
Here, we provide strong evidence of dopaminergic
neurogenesis in the postnatal wild-type mouse brain and
Fig. 7 BNN-20 promotes neuronal differentiation of NSCs in vitro. A,B Dot plots showing the percentages of β-ΙΙΙ tubulin+ neurons in cultures of
A wild-type (WT) SEZ-derived NSCs and B weaver (wv) SEZ- and SN-derived NSCs maintained in differentiation conditions for 5 days with or
without (ctr) BNN-20 addition in the cell medium. C Representative immunofluorescence image of a cell culture stained for βIII tubulin [scale bar
= 50 μm]. D,E Percentages of phosphohistone 3+ (PH3+) cells in cultures of D wild-type (WT) SEZ-derived and E weaver (wv) SEZ- and SN-
derived NSCs, maintained for 5 days in proliferation conditions with or without (ctr) BNN-20 addition in the cell medium [Error bars are SDs. a: p <
0.05 using paired Student t-test analysis because the same cell samples were split in ctr or + BNN-20 conditions. n = 3 independent experiments].
F Representative immunofluorescence image of a cell culture stained for PH3 [scale bar= 50 μm]
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in the “weaver” mouse, a genetic model of gradual
nigrostriatal dopaminergic degeneration. We employed
laborious BrdU-based investigation of cytogenesis in the
SNpc, combined with cell-type profiling for NSPCs and
for cells of the dopaminergic lineage, as well as cell cul-
ture assays. Our key findings are that a constant turn-
over of dopaminergic neurons exists in the normal
postnatal SNpc and that this system can be pharmaco-
logically manipulated with clinically relevant specificity
and efficiency, in order to partially avert the progressive
degeneration of the SNpc in the “weaver” mouse.
Characterization of SNpc neurogenesis
Using long BrdU administration and exhausting confocal
microscopy analysis, we showed that newborn dopamin-
ergic neurons appear in the normal postnatal SNpc,
following a canonical mesencephalic developmental
pathway (expressing the key transcription factor FoxA2).
This is most interesting because by using DiI i.c.v injec-
tions, we showed that NSPCs of the SEZ niche contrib-
ute to this process. These NSPCs are known to generate
TH+ interneurons in the olfactory bulbs (OB) [46] that
we showed to lack expression of FoxA2 and to have dis-
tinct morphology to the typical nigral TH+/FoxA2+
cells. Hence, SEZ cells are able to adjust remarkably to
local requirements, acquiring a mesencephalic fate in the
SNpc or an oligodendroglial fate when recruited in sites
of demyelination in the corpus callosum [47]. When the
system was stimulated in the healthy brain, via the adminis-
tration of BNN-20 in WT mice, neurogenesis in the SNpc
was significantly increased, albeit without an expansion of
the TH+ cell pool, possibly indicating a turnover/ rejuven-
ation mechanism, similar to what has been described in the
OB and the hippocampus [46, 48–50].
The absolute numbers of newborn dopaminergic neu-
rons (BrdU+/TH+) were found to be similar in the WT
and the wv SNpc and, as a result, their representation in
the degenerated wv SNpc was significantly increased.
This suggests that the system of neurogenesis in the
SNpc is insensitive to degeneration and at the same time
indicates that even postnatally born dopaminergic neu-
rons are initially resistant to degeneration, which appears
later, in a time/maturation-dependent pattern. This is in
contrast to previous findings in the 6-OHDA and MPTP
parkinsonian models [24, 25, 27], in which an induction
of dopaminergic neurogenesis was observed in the SNpc
even in vehicle-injected mice [27]. These discrepancies
could be attributed to differences in the models used
(acute mechanical injury versus gradual degeneration)
and the balance between addition and removal of cells,
and indicate that the SNpc neurogenic system responds
differently to different injuries.
An obvious concern is whether the generated TH+
cells are of functional significance. We have recently
Fig. 8 No effect of BNN-20 on BrdU+ cells in the cortex and on astrogliogenesis. A Cell densities of total BrdU+ cells in the SNpc and cortex (CX) of
wild-type (WT) animals after administration of BNN-20 or saline (sal) (P14–P60) [a < 0.01 compared to WT sal]. B Cell densities of total Sox2 expressing
cells in the SNpc and CX WT animals after administration of BNN-20 or sal (P14–P60) [a < 0.01 compared to WT sal]. C Percentage of newborn (BrdU+/
Sox2+) to total Sox2 expressing cells in the WT SNpc and the WT CX after administration of BNN-20 or saline (sal) (P14–P60) [a < 0.05 compared to WT
sal]. D Cell densities of total GFAP+/Sox2+ expressing cells in the WT SNpc and the WT CX after administration of BNN-20 or saline (sal) (P14–P60)
[a < 0.05 compared to WT sal]. Statistical analyses for the data presented in histograms A–D were performed using Student’s t test. n = 3 animals per
group. Error bars are SEMs. E,F Representative immunofluorescence images of triple stainings against BrdU (green), GFAP (red), and Sox2 (white) in
E the SNpc and F the CX of WT animals that received saline (sal) or BNN-20 (P14–P60) [scale bars= 50 μm]
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shown [15] that BNN-20 administration in the wv
mouse, using the same administration scheme (P14–
P60, 100mg/kg b.w. daily, i.p.) that we show here to
lead to the significant induction of dopaminergic neuro-
genesis in the SNpc, results in a 3-fold increase of dopa-
mine levels in the striatum, as well as in significantly
improved locomotor activity. Our results are further
supported by recently published experimental work that
showed very clearly that new nigral neurons, either
grafted or generated via reprogramming [4, 5], can re-
construct the dopaminergic nigrostriatal connection.
A surprising finding was the detection of a, so far, un-
reported TH+ cell fraction, lacking expression of FoxA2.
We showed that these cells are specifically under-
represented in the pool of newly generated TH+ cells,
identified as BrdU+ or DiI+, suggesting that this popula-
tion mainly includes older dopaminergic neurons. That
observation, combined with the marked increase of this
cell type when generation of new cells in the wild-type
SN is boosted by BNN-20, and the fact that their
morphology differs from that of typical nigral dopamin-
ergic neurons, led us to hypothesize that they could
represent dopaminergic neurons that are about to be
eliminated [having lost the expression of FoxA2 which is
critical for the maintenance of the midbrain dopamin-
ergic character [36]], in order to be replaced by newborn
dopaminergic cells. Of course, further analysis is needed,
in order to confirm this hypothesis. However, previously
published experimental work has reported the existence
of dying (TUNEL+) dopaminergic neurons in the wild-
type SNpc, accompanied with no change in the total
dopaminergic cell number [25].
Are all newly generated cells in the SNpc derived from
the SEZ, as suggested by the DiI experiment? This ques-
tion becomes highly relevant ahead of any prospect of
transferring our results in the clinical practice, because
the existence of adult SEZ neurogenesis in the human
brain remains controversial. Several recent reports have
indicated a rapid decline in the generation of SEZ-
derived neuroblasts in the human brain after the 18th
month of age [51, 52] as well as in the context of neuro-
degenerative disorders, including PD. [53–55] However,
earlier work has shown that few of the surviving neuro-
blasts retain active proliferation [56] and can be re-
cruited at remote areas of lesion, for example in cases of
vascular dementia [57]. The capacity of the wv SN to
generate self-renewing neurospheres, in contrast to the
WT tissue, suggests that in the degenerative microenvir-
onment, which is characterized by pro-neurogenic
microglial activation [15], a pool of latent progenitors
could become activated with a prominent neurogenic
output, as has been previously reported for the injured
cortex and midbrain [45, 58]. Notably, the presence of
immature neurons (including TH+) has been reported in
the SN of PD patients [59] and neural progenitor cells
(NPCs) able of in vitro proliferation and neuronal
differentiation have been isolated from the SN of PD
patients, postmortem [60]. Although we failed to detect
Ascl1+ (a marker of non-migrating transit amplifying
progenitors) cells in the SNpc, because Ascl1 is corre-
lated with the generation of interneurons [61], its ab-
sence might be an additional evidence of the operation
of midbrain-specific neurogenesis. On the other hand,
we detected an increased percentage of newborn
(BrdU+/Sox2) Sox2+ cells in the Sox2+ cell pool, after
BNN-20 administration. Because expression of Sox2 is
normally switched off when neuroblasts start to migrate
out of the SEZ [32], its increased expression is compat-
ible with the presence of activated local NSPCs.
The beneficial effects of BNN-20
Our results identify the microneurotrophin BNN-20 as a
potent modulator of neurogenesis in the SNpc. BNN-20
administration led to an impressive, 3-fold to 4-fold in-
crease in the number of newborn dopaminergic neurons,
in the SNpc of both “weaver” and WT mice. This neuro-
genic effect led to the partial restoration of the dopamin-
ergic cell number in the degenerated wv SNpc, while it
did not affect the total dopaminergic cell number in
wild-types. Two of the most clinically relevant findings
on BNN-20 are that its in vivo neurogenic effects are
highly specific in terms of (i) region and (ii) lineage. It
led to increased neurogenesis in the SNpc, without any
effects in the SGZ and the SEZ niches, or in the cortex
[that has previously been shown to harbor dormant
NSPCs [58]], and it did not enhance astrogliogenesis.
BNN-20 exerts its beneficial effects acting as a mimetic
of BDNF, and more specifically, by activating its selective
receptor TrkB and the TrkB-PI2K-Akt-NFκΒ and TrkB-
ERK1/2-NFκΒ downstream pathways [13, 15]. Co-
administration of BNN-20 and ANA-12, a selective TrkB
inhibitor, or the NFκB inhibitor Bay-11-7085, in
“weaver” mice, not only abolished the BNN-20-
dependent increase of BDNF in the SN, but also partially
reversed the preservation of the dopaminergic neurons
of the SNpc [13, 15]. BDNF has been shown to promote
the proliferation, differentiation, migration, and survival
of adult NSCs of the SEZ and the SGZ [62–66], even
though there is still some controversy in the cell-type
expression of the two isoforms of TrkB receptors (the
full-length TrkB-FL and the truncated TrkB-T1) and the
p75NTR pan-neurotrophin receptor, as well as in the ex-
tent of each receptor’s contribution to BDNF’s effect on
adult neurogenesis [38, 61, 64, 65, 67]. The full-length
isoform of TrkB (TrkB-FL), which is able to activate the
PI3K and MAPK downstream signaling cascades [48, 61,
65, 67, 68], is expressed by migrating neuroblasts [61,
65, 69] or the immature neurons of the OB [65, 67], and
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the p75NTR receptor is expressed by intermediate pro-
genitors (type C cells) of the SEZ and neuroblasts [65].
Hence, the effects of BDNF are mainly restricted on the
migration, differentiation, and survival of newborn neu-
rons, and not on the proliferation of the SEZ NSPCs [38,
65]. This is in accordance with our results that suggest
BNN-20 acts mainly to enhance the differentiation of
NSPC into neurons. Finally, these same signaling path-
ways (TrkB-PI3K-Akt and TrkB-ERK1/2) can “jump-
start” ectopic neurogenesis in brain areas such as the
striatum [64].
As mentioned earlier, using DiI tracing experiments,
we have shown that at least part of the newborn dopa-
minergic neurons originates from the SEZ. However, we
failed to detect any significant BNN-20 induced changes
within the SEZ itself. These seemingly contradictory
observations may be explained in two ways. Firstly, the
neurogenic niche of the SEZ is an open system, where
newborn neuroblasts quickly migrate out towards their
target brain area [70]. Hence, a limited increase in the
rate of differentiation of neural progenitors into neuro-
blasts that subsequently migrate towards the SNpc might
not be easily detected in the SEZ. Secondly, the main ef-
fect of BNN-20 could be to enhance the differentiation/
survival of neuroblasts and of their progeny, specifically
in the SNpc.
On the other hand, the SGZ is a closed system, with
BDNF being a key regulating factor [65, 66]. Based on
that, the lack of an effect after BNN-20’s in vivo admin-
istration on hippocampal neurogenesis is unexpected.
However, there are some key differences between the
SEZ and SGZ niches that might offer an explanation.
The expression of neurotrophins (including BDNF) in
the SEZ niche is low, when compared to the SGZ [65].
This means that a BDNF mimetic, such as BNN-20, is
expected to evoke more easily an effect in the “neurotro-
phin poorer” SEZ niche, than in the “BDNF-saturated”
SGZ. Furthermore, the expression patterns of the TrkB
and p75NTR receptors also significantly differ between
the two niches, something that could also result in a
differential activity of BNN-20 [65].
Conclusions
Our results confirm and characterize the existence of
dopaminergic neurogenesis both in the adult wild-type
and the degenerated SNpc of the “weaver” mouse. New-
born dopaminergic neurons appear preferentially resist-
ant to degeneration, as seen by their increased
representation within the total TH+ cell pool of the wv
SNpc, compared to WT. These newborn TH+ neurons
originate, at least partially, from the neurogenic niche of
the SEZ, although we offer evidence for the presence of
local progenitors as well. Moreover, the newborn TH+/
BrdU+ neurons of the SNpc follow the canonical
differentiation pathway, expressing FoxA2 and are pos-
sibly functional. Long-term (P14–P40 or P14–P60) ad-
ministration of the microneurotrophin BNN-20 leads to
a significant enhancement (3-fold to 4-fold) of dopamin-
ergic neurogenesis in the SNpc, in a tissue-specific man-
ner, in both WT and wv mice. While this turnover
supports the partial restoration of the dopaminergic cell
number in the wv SNpc, it does not affect total TH+ cell
numbers in the WT SNpc. Overall, BNN-20 is proved to
be a multi-modal molecule, exhibiting beneficial effects
through an antioxidant and neurotrophic activity [13],
through the modulation of inflammation [15] and, as we
demonstrate here, through the activation of endogenous
NSPCs. The results presented here support BNN-20 as a
promising drug candidate for future cell replacement
therapies against PD, based on the manipulation of the
SNpc’s endogenous regeneration capacity.
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Additional file 1. Graph depicting the administration schemes for BrdU
and BNN-20, used for the in vivo labelling of the newborn TH+/BrdU+
neurons of the SNpc.
Additional file 2. The method used in morphological analysis of TH+
neurons. Three dimensions of dopaminergic neurons were analyzed: the
longest dimension of the cell soma (in yellow), the perpendicular to the
longest (in green) and the shortest (defined by the depth – z, as
indicated at the lowest right corner) [Scale bars = 10 μm].
Additional file 3. BNN-20 administration has no effect on the total
dopaminergic neuron number of the WT SNpc. Total dopaminergic (TH +)
cell number in the SNpc of wild-type (WT) mice, untreated (WT P14, WT
P40, WT P60), or treated with BNN-20 from P14 to P40 (P14-P40) or to P60
(P14-P60) [n = 4 per group. Error bars are SDs; statistical analysis was per-
formed using two-way ANOVA, followed by the Bonferroni post-hoc test].
Additional file 4. Morphology of different dopaminergic cell
populations. Morphological analysis of the 3 dopaminergic neuron
populations shown in Fig. 3A, by comparison of: (A) the longest
dimension, (B) the perpendicular to the longest dimension and (C): the
shortest dimension (depth) of the cell soma. Details are shown in
Additional File 2 [In A: a: p < 0.001 compared to SNpc TH+/FoxA2+
neurons, b: p < 0.05 compared to SNpc TH+/FoxA2- neurons. In C: a: p
< 0.01 compared to SNpc TH+/FoxA2+ neurons, b: p < 0.01
compared to SNpc TH+/FoxA2- neurons. Error bars are SEMs. n = 10
dopaminergic neurons per group. Statistical analysis was performed
using one–way ANOVA (p = 0.000, F = 24.551 in E; p = 0.000, F =
18.849 in G), followed by LSD post hoc analysis.]. (D-E) Characteristic
immunofluorescence images of (D) a TH+/FoxA2+ neuron of the
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SNpc, (E) a TH+/FoxA2- neuron of the SNpc and (F) a TH+/FoxA2-
neuron of the OB [Scale bar = 10 μm].
Additional file 5. DiI staining of the lining of the ventricular systems. DiI
incorporation in the ependymal and subependymal layers of the lateral
ventricles (LV), the third ventricle (3 V) and the Aqueduct (Aq) after one
unilateral DiI injection in the left LV [Scale bars = 500 μm].
Additional file 6. BNN-20 promotes neuronal and astroglial differenti-
ation of NSCs in vitro (additional info). (A,B) Dot plots showing the per-
centages of (A) Dcx + immature neurons and of (B) GFAP+ (astrocytes)
cells in cultures of wild-type (WT) SEZ-derived NSCs maintained in differ-
entiation conditions for (A) 3, 5, 7 or (B) 3 and 7 days with or without (ctr)
BNN-20 addition in the cell medium [Error bars are SDs. a: p < 0.05 using
paired Student t-test analysis because the same cell samples were split in
ctr or + BNN-20 conditions]. (C-D) Representative immunofluorescence
images of cell cultures stained for Dcx (in C) and GFAP (in D) [Scale bars
= 50 μm. n = 3 independent experiments].
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